For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Acquired in-process research and development | 8,517,966 | |||
| Research and development | 368,170 | |||
| General and administrative | 3,727,816 | |||
| Total operating expenses | 12,613,952 | |||
| Loss from operations | -12,613,952 | |||
| Interest income and other, net | 95,472 | |||
| Net loss | -12,518,480 | |||
| Loss attributable to common stockholders | -12,518,480 | |||
| Basic EPS | -129.1 | |||
| Diluted EPS | -129.1 | |||
| Basic Average Shares | 96,967 | |||
| Diluted Average Shares | 96,967 | |||
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)